891 results on '"Metz, Martin"'
Search Results
2. Characterization of cells and mediators associated with pruritus in primary cutaneous T-cell lymphomas
3. Cutaneous Components Leading to Pruritus, Pain, and Neurosensitivity in Atopic Dermatitis: A Narrative Review
4. An update on mechanisms of pruritus and their potential treatment in primary cutaneous T-cell lymphoma
5. Chronische Prurigo
6. Neuropathischer Pruritus
7. Type 2 chronic inflammatory diseases: targets, therapies and unmet needs
8. An emerging aeroallergen in Europe: Tree-of-Heaven (Ailanthus altissima [Mill.] Swingle) inventory and pollen concentrations – Taking a metropolitan region in Germany as an example
9. Similarities and differences in peripheral itch and pain pathways in atopic dermatitis
10. Stepping Down Treatment in Chronic Spontaneous Urticaria: What We Know and What We Don’t Know
11. Inhibition of mast cell degranulation by novel small molecule MRGPRX2 antagonists
12. The 7-day recall period version of the Urticaria Control Test—UCT7
13. Urticarial Vasculitis Differs From Chronic Spontaneous Urticaria in Time to Diagnosis, Clinical Presentation, and Need for Anti-Inflammatory Treatment: An International Prospective UCARE Study
14. Most Patients With Autoimmune Chronic Spontaneous Urticaria Also Have Autoallergic Urticaria, but Not ViceVersa
15. Chronic urticaria and the pathogenic role of mast cells
16. The Classification, Pathogenesis, Diagnostic Workup, and Management of Urticaria: An Update
17. Neuigkeiten aus der aktuellen Leitlinie zu chronischem Pruritus
18. Understanding human mast cells: lesson from therapies for allergic and non-allergic diseases
19. Ligelizumab improves angioedema, disease severity and quality-of-life in patients with chronic spontaneous urticaria
20. A Systematic Review of Aquagenic Urticaria—Subgroups and Treatment Options
21. Urticaria
22. Inducible Urticarias
23. Benralizumab does not elicit therapeutic effect in patients with chronic spontaneous urticaria: results from the phase IIb multinational randomized double-blind placebo-controlled ARROYO trial.
24. Fenebrutinib in H.sub.1 antihistamine-refractory chronic spontaneous urticaria: a randomized phase 2 trial
25. Targeting histamine receptor 4 in cholinergic urticaria with izuforant (LEO 152020): results from a phase IIa randomized double-blind placebo-controlled multicentre crossover trial
26. Efficacy of Remibrutinib in Patients With Chronic Spontaneous Urticaria With or Without Prior Exposure to Biologics in the Phase 3 REMIX-1 and REMIX-2 Studies
27. Barzolvolimab Significantly Decreases Chronic Spontaneous Urticaria Disease Activity and is Well Tolerated: Top Line Results from a Phase 2 Trial
28. MRGPRX2 Small Molecule Antagonists Potently Inhibit Agonist-Induced Skin Mast Cell Degranulation
29. CRUSE®—An innovative mobile application for patient monitoring and management in chronic spontaneous urticaria
30. Sleep disturbance in adult dermatologic patients: A cross-sectional study on prevalence, burden, and associated factors
31. The Diagnostic Workup in Chronic Spontaneous Urticaria—What to Test and Why
32. The characteristics and impact of pruritus in adult dermatology patients: A prospective, cross-sectional study
33. Pruritus ani – Diagnostik und Therapie: Empfehlungen aus der aktualisierten Leitlinie
34. Expert consensus on practical aspects in the treatment of chronic urticaria
35. Validation of the Angioedema Control Test (AECT)—A Patient-Reported Outcome Instrument for Assessing Angioedema Control
36. The role of eosinophils in chronic spontaneous urticaria
37. Management of urticarial vasculitis: A worldwide physician perspective
38. Eosinopenia, in Chronic Spontaneous Urticaria, Is Associated with High Disease Activity, Autoimmunity, and Poor Response to Treatment
39. In the skin lesions of patients with mycosis fungoides, the number of MRGPRX2-expressing cells is increased and correlates with mast cell numbers
40. Differential diagnosis between urticarial vasculitis and chronic spontaneous urticaria: An international Delphi survey
41. Arzneitherapie des chronischen Pruritus – Licht am Ende des langen Tunnels?
42. Mast cells as protectors of health
43. The Classification, Pathogenesis, Diagnostic Workup, and Management of Urticaria: An Update
44. Omalizumab Updosing in Chronic Spontaneous Urticaria: an Overview of Real-World Evidence
45. Pruritus and sleep disturbances in patients with psoriasis
46. Mast cells and IgE in defense against lethality of venoms: Possible “benefit” of allergy
47. Development and Validation of a Patient-Reported Outcome Measure to Assess Disease Control in Chronic Prurigo.
48. Mast cell silencing: A novel therapeutic approach for urticaria and other mast cell‐mediated diseases.
49. CRUSE®—An innovative mobile application for patient monitoring and management in chronic spontaneous urticaria.
50. Efficacy and safety of on‐demand versus daily rupatadine in chronic spontaneous urticaria: A randomized trial.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.